OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 09:26 UTC. Every row links to its source record.

FUBP1 far upstream element binding protein 1

ENSG00000162613 · protein coding · Open Targets profile

Regulates MYC expression by binding to a single-stranded far- upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription. .

In 12 of 15 cancers, the evidence for FUBP1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.46lymphoid neoplasm: germline 0.68lung carcinomalung carcinomalung carcinoma: somatic 0.46lung carcinoma: germline 0.60low grade gliomalow grade gliomalow grade glioma: somatic 0.69cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.46cutaneous melanoma: germline 0.54gliomagliomaglioma: somatic 0.61anaplastic oligodendrogliomaanaplastic oligodendrogliomaanaplastic oligodendroglioma: somatic 0.61colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61gastric carcinomagastric carcinomagastric carcinoma: somatic 0.61skin squamous cell carcinomaskin squamous cell carcinomaskin squamous cell carcinoma: somatic 0.61brain oligodendrogliomabrain oligodendrogliomabrain oligodendroglioma: somatic 0.61bile duct carcinomabile duct carcinomabile duct carcinoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61Transitional MeningiomaTransitional MeningiomaTransitional Meningioma: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.16854999959468842 (upper bound 0.25600001215934753). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of FUBP1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of FUBP1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.